Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 17/20 | 0.75 |
| ▸ | SIRT1 | Q96EB6 | 12/20 | 0.75 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.67 |
| ▸ | SIRT3 | Q9NTG7 | 9/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23702277 | 1.00 | SIRT2 (0.75) | SIRT2SIRT1FOLH1SIRT3 | |
| SCHEMBL20542631 | 0.93 | SIRT2 (0.74) | SIRT2SIRT1SIRT3 | |
| SCHEMBL20543121 | 0.93 | SIRT2 (0.74) | SIRT2SIRT1SIRT3 | |
| SCHEMBL20543119 | 0.93 | SIRT2 (0.74) | SIRT2SIRT1SIRT3 | |
| SCHEMBL20542633 | 0.93 | SIRT2 (0.74) | SIRT2SIRT1SIRT3 | |
| SCHEMBL20543157 | 0.93 | SIRT2 (0.74) | SIRT2SIRT1SIRT3 | |
| SCHEMBL20543026 | 0.93 | SIRT2 (0.74) | SIRT2SIRT1SIRT3 | |
| SCHEMBL20543029 | 0.93 | SIRT2 (0.74) | SIRT2SIRT1SIRT3 | |
| SCHEMBL20542849 | 0.93 | SIRT2 (0.74) | SIRT2SIRT1SIRT3 | |
| SCHEMBL20543156 | 0.93 | SIRT2 (0.74) | SIRT2SIRT1SIRT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10765656-B2 | Isothiocyanate functional compounds augmented with secondary antineoplastic medicaments and associated methods for treating neoplasms | THE WILLIAM M. YARBROUGH FOUNDATION (US) | 2020-09-08 | — | — | US | disclosed |
| US-20200179324-A1 | ISOTHIOCYANATE FUNCTIONAL COMPOUNDS AUGMENTED WITH SECONDARY ANTINEOPLASTIC MEDICAMENTS AND ASSOCIATED METHODS FOR TREATING NEOPLASMS | THE WILLIAM M. YARBROUGH FOUNDATION | 2020-06-11 | — | — | US | disclosed |
| US-20180037545-A1 | ISOTHIOCYANATE FUNCTIONAL SURFACTANTS, FORMULATIONS INCORPORATING ISOTHIOCYANATE FUNCTIONAL SURFACTANTS AND ASSOCIATED METHODS FOR TREATING BIOFILMS | THE WILLIAM M. YARBROUGH FOUNDATION | 2018-02-08 | — | — | US | disclosed |
| US-20170239207-A1 | Method for Treating Skin Cancer | THE WILLIAM M. YARBROUGH FOUNDATION | 2017-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180037545-A1 | ISOTHIOCYANATE FUNCTIONAL SURFACTANTS, FORMULATIONS INCORPORATING ISOTHIOCYANATE FUNCTIONAL SURFACTANTS AND ASSOCIATED METHODS FOR TREATING BIOFILMS | CFTR, TST, CBS | SIRT2 537/4885SIRT1 531/4885FOLH1 1249/4885 |
| US-20170239207-A1 | Method for Treating Skin Cancer | MGMT, KRT18, TYR | SIRT2 1868/4885SIRT1 2270/4885FOLH1 1016/4885 |
| US-10765656-B2 | Isothiocyanate functional compounds augmented with secondary antineoplastic medicaments and associated methods for treating neoplasms | TP53, GSTA2, GSTA1 | SIRT2 1046/4885SIRT1 1288/4885FOLH1 624/4885 |
| US-20200179324-A1 | ISOTHIOCYANATE FUNCTIONAL COMPOUNDS AUGMENTED WITH SECONDARY ANTINEOPLASTIC MEDICAMENTS AND ASSOCIATED METHODS FOR TREATING NEOPLASMS | TP53, GSTA2, GSTA1 | SIRT2 1046/4885SIRT1 1288/4885FOLH1 624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.